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ABSTRACT
Aging is a biological process that affects most cells, organisms and species. Human aging is
associated with increased susceptibility to a variety of chronic diseases, including cardiovascular
disease, Type 2 diabetes, neurological diseases and cancer. Despite the remarkable progress made
during the last two decades, our understanding of the biology of aging remains incomplete.
Telomere biology has recently emerged as an important player in the aging and disease process.
INTRODUCTION
The 2009 Nobel Prize in Physiology or Medicine
was awarded jointly to Dr Elizabeth H. Blackburn,
Dr Carol W. Greider and Dr Jack W. Szostak for
their pioneer research on telomeres and the enzyme
that forms them, telomerase. Telomeres are specialized
structures located at the terminal ends of chromosomes
and play a critical role in maintaining the integrity
of the genome. In proliferating cells lacking functional
telomerase, telomeres progressively shorten during every
mitotic division, and the cells eventually undergo
senescence. Therefore, telomere length shortening has
been recognized as not only a marker of biological
aging but also a mechanism with important functional
consequences. However, telomere shortening is not the
only factor that dictates cell fates. The presence of
telomerase itself, a buffer against telomere shortening,
is another critical factor. Not only is telomere biology
involved in the biological process of aging, but it
has been also postulated to play a role in multiple
aging-associated diseases and conditions. In the present
review, we will discuss the role of telomere biology
in CVD (cardiovascular disease) and neurodegenerative
diseases. The role of telomere biology in cancer has been
extensively discussed in several recent reviews [1−4].
THE TELOMERE COMPLEX
Telomeres are specialized DNA structures located at
the terminal ends of the chromosomes [5]. Their
primary function is to maintain genome stability.
Telomeresconsistofnon-codingdouble-strandedrepeats
of guanine-rich tandem DNA sequences (TTAGGG)
that are extended 9–15 kb in humans and end in a 50–
300 nucleotide 3  single guanine strand overhang [6].
This overhang can fold back and invade the double-
stranded telomere helix, forming a large ‘T-loop’. The
T-loop facilitates the formation of a high-order structure
mediating the end-capping [7] (Figure 1). The stability
of the T-loop is largely dependent on the integrity of
the associated telomere-speciﬁc proteins, also called the
shelterin complex [8] (Figure 2). The proteins involved
in the shelterin complex include TRF (telomeric repeat-
binding factor) 1 and TRF2, which bind to the double-
stranded segment of telomeric DNA [9,10]. POT1
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Figure 1 Simpliﬁed diagram depicting the structure of the telomere and its location on the chromosome and in the cell
This Figure was reproduced from Huzen, J., van Veldhuisen, D.J., van Gilst, W.H. and van der Harst, P. (2008), Telomeres and biological ageing in cardiovascular
disease, Ned. Tijdschr. Geneeskd., vol. 152, pp. 1265−1270, with permission from the Nederlands Tijdschrift voor Geneeskunde.
Figure 2 Simpliﬁed scheme depicting the terminal end of the telomere concealing the terminal single-stranded part with
help of the shelterin complex
This Figure was reproduced from Huzen, J., van Veldhuisen, D.J., van Gilst, W.H. and van der Harst, P. (2008), Telomeres and biological ageing in cardiovascular
disease, Ned. Tijdschr. Geneeskd., vol. 152, pp. 1265−1270, with permission from the Nederlands Tijdschrift voor Geneeskunde.
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Figure 3 Schematic overview of telomerase
Active telomerase is composed from two RNA complexes (TERC; only one depicted) and two telomere reverse transcriptases (TERC; one depicted) stabilized by dyskerin.
This Figure was reproduced from Huzen, J., van Veldhuisen, D.J., van Gilst, W.H. and van der Harst, P. (2008), Telomeres and biological ageing in cardiovascular
disease, Ned. Tijdschr. Geneeskd., vol. 152, pp. 1265−1270, with permission from the Nederlands Tijdschrift voor Geneeskunde.
(protein protection of telomeres 1) binds directly to the
single-stranded telomeric DNA and interacts directly
with TPP1 (tripeptidyl peptidase 1) [11]. Rap1 (repressor
activator protein 1) binds TRF2 [12], and TIN2 (TRF1-
interacting nuclear factor 2) is a central component of the
complex interacting with TRF1, TRF2 and TPP1 [13,14].
The telomere complex plays a critical role by protect-
ing the chromosomes from recognition by the DNA
damage-repair system as DNA ‘breaks’ and activation
of the p53 or p16INK4a pathway, eventually leading to
cellular senescence or apoptosis [15].
Owing to the inability of DNA polymerase to fully
replicate the 3  end of the DNA strand, i.e. the ‘end-
replicationproblem’,thetelomeresnaturallyloseapprox.
30−150 bp with each cell division [16]. Furthermore,
telomere erosion can occur due to environmental factors,
especially ROS (reactive oxygen species). Eventually,
telomeres will reach a critical short length resulting in a
decreased ability to recruit shelterin proteins and to form
the protective internal nucleotide loops. This impairment
will lead to the activation of the p53 or p16INK4a pathway
and result in cellular senescence or apoptosis [3]. On
average, cells are estimated to reach this ‘Hayﬂick limit’
afterapprox.50populationdoublings[17].Itisimportant
to realize that not only the shortened telomeres, but also
disruption of the associated shelterin proteins, can lead
to the inability to protect the integrity of the genome.
THE TELOMERASE COMPLEX
Telomere shortening is not the only factor that dictates
cell fates. The presence of telomerase itself is another
critical factor [18]. Telomerase not only functions to
maintain telomere length [19], but also preserves healthy
cell function and long-term immune function [18,20].
When telomerase is active, a ‘mitotic clock’ model
does not apply; by stabilizing telomeres, telomerase
effectively moves back the hands of any such ‘clock’.
Active telomerase helps even very short telomeres to be
functional [18]. Human telomerase consists of a RNA
component [TERC (telomerase RNA component)] that
serves as a template and a catalytic subunit of telomerase
[TERT(telomerasereversetranscriptase)]thatisrequired
for the synthesis of new telomeric DNA repeats
(Figure 3). The 5  end of TERC contains the template
region and the 3  end of TERC contains two binding sites
for additional telomerase-associated proteins. Together
with NHP2, NOP10 and GAR1, dyskerin binds to an
H/ACA box, which is essential for telomerase assembly
andstability[21].TCAB1(telomeraseCajalbodyprotein
1) interacts with dyskerin, which is crucial for facilitating
telomerase trafﬁcking to the Cajal body (CAB box) and
for telomere maintenance [22].
In addition to the widely appreciated telomere
maintenance function, new roles of telomerase have
recently been suggested. Loss of TERT does not alter
short-term telomere integrity but, instead, affects the
overall conﬁguration of chromatin and impairs the DNA
damage response [23]. In addition, TERT can promote
proliferation of resting stem cells [24]. Moreover,
telomerase directly modulates Wnt/β-catenin signalling
by serving as a cofactor in a β-catenin transcriptional
complex [25]. Wnt/β-catenin signalling plays a crucial
role not only during embryogenesis, but also in normal
adult tissue genesis. Emerging evidence suggests that
Wnt signalling is involved in cardiac differentiation and
development [26], angiogenesis, cardiac hypertrophy,
cardiac failure and aging [27].
TELOMERE LENGTH DETERMINANTS
Telomere length is highly variable among individuals
at the same age and to a large extent genetically
determined, with heritability estimates ranging from 40
to80%.Genome-wideassociationstudieshaveidentiﬁed
associated loci on chromosome 18q12.2 [28], 3q26 (near
TERC) [29] and 10q24.33 [30].
Telomere lengths are highly synchronized among the
DNA samples from white blood cells, umbilical artery
and skin within individual newborns, but exhibited
a high variability among newborns [31]. In addition,
telomere lengths become more heterogeneous among
different organ tissues in the elderly [32]. Despite
no differences in telomere length between African
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American and Caucasian or male and female newborns
[31], African American adults have longer telomeres
than their Caucasian counterparts [33], and adult
males generally have shorter telomeres than females
[34]. A recent study conducted in 667 Caucasian
and African American adolescents showed that the
ethnicity and sex differences in telomere length have
already emerged during adolescence [35]. Women also
exhibit a signiﬁcantly lower rate of age-dependent
telomere attrition as compared with men [36], possibly
due to the stimulating properties of oestrogen on
telomerase. A remarkable association between the levels
of oestrogen and telomerase activity has been shown
under physiological conditions [37]. Studies in vitro
showthatoestrogenrapidlyup-regulatestelomerasegene
expression and activity [38].
Telomere length is not only genetically determined,
but also shaped by environmental factors. Owing to the
high content of guanine residues, telomeres are highly
sensitive to damage by oxidative stress. The contribution
to the telomere loss by oxidative DNA damage is
believed to be greater than by the ‘end-replication
problem’ [39]. Prolonged oxidative damage also dra-
matically decreases telomerase activity and accelerates
telomere shortening in vascular smooth muscle cells
and endothelial cells [40]. Conversely, addition of
antioxidants decelerates telomere shortening in cultured
cells and prolongs telomerase activity [41]. Systemic
oxidative stress assessed by urinary 8-epiprostaglandin
F2α is associated with shorter leucocyte telomeres in
hypertensive men from the Framingham Heart Study
[42]. A higher level of oxidized LDL (low-density
lipoprotein)isassociatedwithshorterleucocytetelomere
length and increased stiffness of the carotid artery [43].
Inﬂammationisalsothoughttocontributetotelomere
attrition in cells of the immune system by promoting
leucocyte turnover. An increased production of certain
cytokines has been shown to adversely affect telomerase
activity and telomere length [44]. CRP (C-reactive
protein),anindexofinﬂammation,isinverselycorrelated
with leucocyte telomeres in premenopausal but not
postmenopausal women [45]. Shorter telomeres have
been related to higher IL-6 (interleukin-6) and CRP in
haemodialysis patients [46] and in men [47].
Psychological and life stress have been shown to be
signiﬁcantly associated with higher levels of oxidative
stress, lower telomerase activity and shorter leucocyte
telomere lengths. Decreased perceived mental health is
associated with shorter leucocyte telomeres in patients
with CHF (chronic heart failure) [48]. Most strikingly,
childhood mistreatment, adverse life events, chronic and
serious illness are associated with shorter telomeres later
in life [49]. Smoking is typically marked by an increased
oxidative stress and inﬂammation in concert with
shortened telomere length [43]. Female smokers tend to
have shorter telomeres, and smoking reduces telomere
length in a dose-dependent manner [50]. Physical activity
has been positively associated with telomere length
in adults [51] and in adolescents [35], suggesting an
anti-aging beneﬁt. Increased dietary intake of marine
ω−3 fatty acids is associated with prolonged survival
in patients with coronary heart disease. Farzaneh-
Far et al. [52] recently showed that individuals in
the lowest quartile of DHA+EPA (docosahexaenoic
acid+eicosapentaenoic acid) experienced the fastest
telomereshortening,whereasthoseinthehighestquartile
experiencedtheslowesttelomereshorteningover5 years.
Each S.D. increase in DHA+EPA levels was associated
witha32%reductionintheoddsoftelomereshortening.
Other lifestyle factors such as socioeconomic status also
have an impact on telomere length [53].
REGULATION OF TELOMERASE FUNCTION
Telomerase function is also regulated by genetic,
epigenetic and environmental factors. Although most
genes involved in telomere biology are highly conserved
between species and have limited genetic diversity in
humans [54], several polymorphisms in the TERT
promoter region and genes coding for telomerase-
associated proteins have been shown to regulate
telomerase gene expression and activity level [55−58].
It is becoming increasingly apparent that epigenetic
modiﬁcations including CpG methylation, histone
methylation and acetylation is important for TERT
transcriptional regulation [59−61].
Chronic life stress is linked to shorter telomeres and
hasbeenassociatedwithreducedtelomeraseactivity[62].
Oxidized LDL and TNF-α (tumour necrosis factor-
α) were inversely correlated to telomerase activity in
haemodialysis patients [63]. Numerous in vitro studies
demonstrate that oxidative stress and inﬂammation
reduce telomerase activity and shorten telomere length
in cultured endothelial progenitor cells, human-derived
ﬁbroblasts and neoplastic cells [64−67]. Lifestyle
factors are also important regulators of telomerase
function. Exercise increased aortic telomerase activity
and telomere-stabilizing proteins in mice. Additionally,
exercise down-regulated vascular cell-cycle inhibitors
and apoptosis regulators, and this down-regulation was
completelyabsentinTERT −/− mice.Youngandmiddle-
aged athletes were also characterized by a profound up-
regulation of telomerase activity and telomere proteins
as well as down-regulation of pro-apoptotic proteins
compared with untrained individuals [68]. Ornish
et al. [69] conducted a 3-month comprehensive lifestyle
intervention (including nutrition and physical activity)
in 24 low-risk prostate cancer patients and showed
that, by the end of 3 months, PBMC (peripheral blood
mononuclear cell) telomerase activity had increased by
29%. That study is important because it shows that
C   The Authors Journal compilation C   2011 Biochemical Society
© 2011 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Healthy aging and disease: role for telomere biology? 431
PBMC telomerase activity is not only measurable, but
also might be boosted by healthy lifestyle behaviours.
Regulationoftelomeraseactivityisnotonlycontrolled
at the level of TERT transcription, but also at the
post-transcriptional level [70]. Phosphorylation and
nuclear translocation both play an important role
in the post-transcriptional regulation of telomerase
activity [71]. Several pathways are involved in TERT
post-transcriptional regulation such as the PI3K
(phosphoinositide 3-kinase)/Akt signal transduction
pathway. Resveratrol, a drug compound, possesses
diverse biochemical and physiological actions, including
cardioprotective properties and has been shown to
increase telomerase activity through increased Akt
phosphorylation [72]. ACEIs (angiotensin-converting
enzyme inhibitors) promote endothelial cell survival
and prolong their lifespan partly through increased
telomerase function by Akt phosphorylation [73].
Recently, the notion that telomeres are transcrip-
tionally silent has been challenged. TERRA (telomeric
repeat-containing RNA) is a new addition to the
telomeric ribonucleoprotein complex [74−76]. TERRA
is a heterogeneous non-coding RNA that consists of
a combination of subtelomeric and telomeric region
that can form an intermolecule G-quadruplex structure
with telomeric DNA repeats. TERRA is transcribed
in a centromere to telomere direction, indicating that
the transcriptional start site lies within the subtelomeric
sequence [74−76]. In mammals, TERRA ranges between
100 and 9 kb, is expressed in most tissues, and
is regulated by the nonsense-mediated RNA decay
machinery [77,78]. TERRA displays a strong inverse
correlation with telomerase activity [76,79]. Emerging
evidence suggests that TERRA plays important roles in
the regulation of telomerase, maintaining higher-order
telomeric chromatin structure and mediating several
crucial functions of the telomeres [74,77].
TELOMERE BIOLOGY IN STEM CELLS
Stemcellsregenerateourbody.Telomeresandtelomerase
are main components of the stem cell ‘ignition’
mechanism, providing a way to restrain cancer and
delay aging [80]. Stem cells and progenitor cells play
an important role in maintaining tissue homoeostasis by
replenishing senescent or apoptotic cells and repairing
damage that occurs throughout life. Exhaustion of the
stem cell or progenitor cell pool is a signiﬁcant risk factor
in the aging process [81]. Stem cells are able to divide
past the Hayﬂick limit due to the presence of telomerase.
Normal tissue stem cells show progressive telomere
shortening with age, and telomerase is highly regulated.
Conversely, telomere length is maintained in cancer cells,
and telomerase is continuously expressed [82]. Stem
cell populations in various compartments of the body
maintain telomeres of different lengths, with the longest
telomeres observed in the testis, skin, small intestine,
cornea and brain. Male germ cells are exceptional because
theirtelomeresactuallygetlongerwithagingpresumably,
in part, due to high telomerase activity. Additionally, less
differentiated stem cells maintain longer telomeres than
more differentiated cells [83]. Haematopoietic stem cells
giverisetothevarioustypesofbloodcells.Althoughthey
express telomerase, it is insufﬁcient to maintain telomere
length, and they undergo a functional decline with age
correspondingtodecreasedregenerativecapacity.Indeed,
the age of the donor in bone marrow transplantation
is signiﬁcant for recipient survival [84]. Telomerase
activity is increased in haematopoietic stem cells upon
immune stimulation allowing for rapid clonal expansion
in response to antigen. Human embryonic stem cells dis-
play greater telomere stability than adult stem cells,
possiblyduetoincreasedDNAmaintenanceordecreased
oxygen radicals [85].
TELOMERE BIOLOGY AND HUMAN
AGING-ASSOCIATED DISEASES
The role of dysfunctional telomere biology in cancer is
well established. Several anti-cancer drugs and cancer
vaccinesthattargetthetelomeraseareinPhaseIIIclinical
trials. By contrast, the role of telomere biology in the
development of aging-related diseases, including CVD, is
onlypartlyunderstood,despitetheprogressmadeduring
the last decade.
CVD
CVD is the leading cause of death worldwide. The
cardiovascular system is a vital organ system mostly
affected by the aging process. Unfortunately, aetiologies
of CVD remain largely unknown, which hampers
prevention and treatment efforts. Although genetic and
environmental factors are clearly responsible, common
genetic variants identiﬁed by genome-wide association
studies, so far, confer relatively small increments in risk
andexplainonlyasmallproportionoffamilialclustering.
Rarevariants,telomeredysfunctionandepigeneticeffects
are most likely to account for the missing heritability
[86,87]. Indeed, evidence for an association between
circulating leucocyte telomere length and CVD is rapidly
accumulating [88].
Hypertension
One in three U.S. adults suffers from hypertension. Data
from animal and human studies suggest that telomere
dysfunction and hypertension may be causally linked.
TERT expression and telomerase activity were increased
in the aortae of SHR (spontaneous hypertensive rats)
at ages preceding the establishment of hypertension
[89]. Moreover, TERC−/− mice show increased
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ET-1 (endothelin-1) production and develop hyperten-
sion [90]. Endothelial progenitor cells from hypertensive
patientsandfromSHRexhibitreducetelomeraseactivity
and accelerate senescence [91]. A study of 49 adult
twin pairs found that telomere length was inversely
associated with pulse pressure. Both telomere length
and pulse pressure are highly familial [92]. Men with
shorter telomere length were more likely to exhibit
higher pulse pressure and pulse wave velocity [93].
Pulse pressure is a clinical marker of large artery
stiffness that increases with chronological age and is
a predictor of cardiovascular mortality and morbidity.
In pre-hypertension and established hypertension, the
RAS (renin−angiotensin system) is often activated.
Telomere length was found to be shorter in individuals
with a higher renin/aldosterone ratio, especially in
participants with hypertension in the Framingham
Heart Study [94]. Moreover, shorter telomere length
was associated with hypertension, increased insulin
resistance and oxidative stress in the offspring cohort
of the Framingham Heart Study [42]. Furthermore,
normotensive individuals with shorter telomeres were
more likely to develop hypertension, and hypertensive
subjects with shorter telomeres were more susceptible to
develop atherosclerosis [95].
Atherosclerosis
Atherosclerosis is also an aging-related systemic disease
with early origins. A tight interplay between cell
senescence and atherosclerosis has been suggested by
invitroandinvivostudies.Senescent-positiveendothelial
cells can be found in almost any atherosclerotic
plaque, and endothelial dysfunction is recognized as
one of the earliest events of atherosclerosis [96]. The
endothelial and smooth muscle cells in the vessel,
which are most susceptible to develop atherosclerosis,
are highly proliferative and highly subjected to stress
by increased mean arterial pressure, cholesterol and
oxidative stress [81]. In complicated plaques, senescence
of various cell types, including vascular smooth muscle
cells and macrophages, favours both plaque rupture
and atherothrombosis [97]. Cell senescence induced by
telomere shortening contributes to the development of
atherosclerosis. The pioneer clinical study, conducted
by Samani et al. [98] in 2001, showed that leucocyte
telomerelengthwas303 bpshorterinpatientswithsevere
coronaryarterydiseasethanthatinage-matchedcontrols,
which is equivalent to 8.6 years of aging. Later, large-
scale studies conﬁrmed these ﬁndings. A retrospective
survey of 203 subjects with a premature myocardial
infarction before the age of 50 and 180 controls showed
that age- and sex-adjusted mean telomere length of cases
was 300 bp shorter than that of controls and on average
equivalent to controls 11.3 years older [99]. Farzaneh-
Far et al. [100] measured telomere length of 780 patients
with stable coronary artery disease in the Heart and
Soul Study; patients in the lowest quartile of telomere
length remained at signiﬁcantly increased risk of death
compared with those in the highest quartile and were
also at signiﬁcantly increased risk of hospitalization for
heart failure, suggesting a prognostic value of short
telomeres. In the West of Scotland Primary Prevention
Study of 1542 participants, subjects in the middle
and the lowest tertiles of telomere length were more
at risk of developing a coronary heart disease event
than were those in the highest tertile; moreover, statin
treatment was more beneﬁcial to patients with short
telomeres [101]. The Bruneck Study, a population-based
prospective study, recently unraveled a highly signiﬁcant
association between short telomeres and cardiovascular
risk, independently of age, sex and standard risk factors.
Remarkably, telomere length was strongly associated
with advanced, but not early, atherosclerosis [102].
In addition, leucocyte telomere length is negatively
associated with the presence of coronary atherosclerosis
in a low-risk middle-aged cohort free of previously
diagnosed CVD [103]. Importantly, healthy lifestyle
behaviours might attenuate the association between
shorter telomere length and coronary atherosclerosis
[104].
Heart failure
Heart failure is a common, costly, disabling and
potentially deadly condition. It is associated with a high
health expenditure of more than $35 billion annually
in the U.S.A. Advanced age is one of the major risk
factors for the development of CHF (chronic heart
failure), and CHF is characterized by increased myocyte
apoptosis and telomere erosion [105]. Data from animal
studiessuggestaroleoftelomeredysfunctioninmyocyte
apoptosis and CHF. Telomere shortening in G2 and
G5 TERC−/− mice was coupled with attenuation in
cardiac myocyte proliferation, increased apoptosis and
cardiacmyocytehypertrophy.Eventually,leftventricular
failure and pathological cardiac remodelling developed in
later generations of TERC−/− mice with critically short
telomeres [106].
Patients with CHF have 40% reduced telomeres
compared with age- and gender-matched controls, and
the degree of telomere shortening is associated with the
severity of disease [107]. Moreover, shorter telomeres are
associated with decreased renal function, worse outcome
in patients with CHF, possibly due to dropout of
functional nephrons [81,108]. One S.D. longer telomeres
are associated with a 5% higher left ventricular ejection
fraction, and telomere length accounts for 12% of
the observed variability in ejection fraction in subjects
of 85 years and older [109]. In aged diseased hearts
characterized by moderate hypertrophy and dilation, cell
death markedly increased and occurred only in cells
expressing a p16INK4a pathway that had signiﬁcant te-
lomere shortening [110]. Additionally, shorter telomeres
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increase the risk of having anaemia associated with
poor prognosis in CHF patients [111]. In a longitudinal
study of 890 patients with New York Heart Association
functional class II to IV heart failure, patients with
shorter telomeres were at an increased risk (1.79-fold)
of reaching the primary end point (time to death or
hospitalization for heart failure) 18 months later. Short
telomeres might predict the occurrence of death or
hospitalization in patients with chronic heart failure
[112].
Diabetes
T2D (Type 2 diabetes), another aging-related disorder, is
caused by a combination of peripheral insulin resistance
and β-cell dysfunction. Recent evidence, however,
suggests that T2D is additionally characterized by
impaired β-cell regeneration and reduced β-cell mass
[113,114]. Shortened telomeres have been previously
associated with diabetes in several small-scale studies,
which has been recently conﬁrmed by two large studies
[115,116]. Zee et al. [115] studied 432 Caucasian T2D
cases and 424 controls; telomeres were shorter in cases
than in controls, and shorter telomeres were signiﬁcantly
associated with T2D (adjusted odds ratio=1.748). Salpea
etal.[116]studied569Caucasian,103SouthAsianand70
Afro-Caribbean T2D patients and 448 healthy controls;
shorter telomeres were associated with the presence of
T2D and this could be partially attributed to the high
oxidative stress in these patients. Interestingly, short
telomeres are independent predictors of progression
of diabetic nephropathy in patients with T1D (Type
1 diabetes), an early-onset disease, although telomere
length was not different in T1D patients compared with
healthycontrols[117].Alongitudinalstudywith11 years
follow-upshowedthatshorttelomeresalsopredictedall-
cause mortality in T1D patients [118]. Additionally, both
T1D and T2D patients demonstrate shorter telomeres
in their arterial walls. Telomere shortening in both
mononuclear cells and arterial cells can be reduced
by controlling blood sugar levels in both types of
diabetes mellitus. Moreover, the mononuclear telomere
attrition was completely prevented by adequately
glycaemic control in T2D [119]. Pre-diabetes patients
with impaired glucose tolerance also display shorter
telomeres than healthy controls, and diabetic patients
with atherosclerotic plaques display shorter telomeres
than diabetic patients without atherosclerosis [120].
Obesity and insulin resistance are also associated with
leucocyte telomere length among adult Arabs [121].
Recently,adirectcausallinkbetweenimpairedtelomerase
activity and impaired insulin secretion as well as glucose
intolerance was reported. Young adult TERC−/− mice
exhibited impaired glucose tolerance, which was caused
by impaired glucose-stimulated insulin secretion from
pancreatic islets. The impaired insulin secretion capacity
was due to reduced islet size, which was linked to an
impairedreplicationcapacityofinsulin-producingβ-cells
in TERC−/− mice [122].
Telomerase dysfunction and CVD
Despite the evidence of telomere shortening in the
development of CVD, little is known about the role
of telomerase dysfunction in the development of CVD.
Existing evidence is mostly from animal research. For
example, TERT transgenic mice exhibited a reduced
myocardial infarct area after coronary artery ligation,
and exogenous TERT expression in cardiac myocytes
promoted survival [123]. In addition, TERT transgenic
mice showed signiﬁcant resistance to ischaemic brain
injury [124]. Conversely, TERT −/− mice are more
susceptible to oxidative stress and to the development
of stroke [125]. Werner et al. [126] showed that exercise
increased telomerase activity and TERT and TRF2
expression in wild-type mice, but not in TERT −/− mice.
This suggests that, in the absence of telomerase, up-
regulation of telomere-stabilizing proteins is challenged,
and cardiac apoptosis is more severe [127]. Similarly,
TERC−/− mice are also well studied. Perez-Rivero
et al. [90] reported a direct link between telomerase
activity and hypertension. TERC−/− mice exhibited
higher ECE (endothelin-converting enzyme) expression,
thus increased ET-1 (endothelin-1) production and de-
veloped hypertension. Moreover, endothelial progenitor
cells from hypertensive patients and from SHR exhibit
reduced telomerase activity and accelerated senescence
[91]. Late generation TERC−/− mice had diminished
angiogenesis potential compared with wild-type mice
[128] and suffered from severe left ventricular failure,
cardiacstructurechangeandmyocytehypertrophy[106].
Despite the promising data from the mouse models,
most ﬁndings have not been translated back to human
studies [127]. One of the challenges faced by large-scale
human epidemiological studies is the requirement of
freshly processed PBMCs, which prevents the usage
ofmanyexistingcohorts.Thereareonlyafewsmall-scale
human studies available. The pioneering work conducted
by Epel et al. [129] showed that low leucocyte telomerase
activity was associated with the major risk factors for
CVD,includingsmoking,poorlipidproﬁle,highsystolic
blood pressure, fasting glucose and greater abdominal
adiposity, in 62 healthy premenopausal women, whereas
no association was found between telomere length and
CVD risk factors. Therefore they proposed that low
leucocytetelomeraseconstitutesanearlymarkerofCVD
risk,possiblyprecedingshortenedtelomeres.Inaddition,
this relationship could result, in part, from chronic stress
arousal. A couple of other small-scale studies have also
showedthattelomeraseactivityofPBMCswasdecreased
in rheumatoid arthritis patients [130] and haemodialysis
patients [131].
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AD (Alzheimer’s disease)
AD, the major cause of dementia in the elderly,
is an aging-associated progressive neurodegenerative
disorder. Telomere dysfunction emerged as a potential
contributor to the pathogenesis of AD. AD patients
have signiﬁcantly shorter leucocyte telomere length than
age-matched controls [132−134]. Older females with
Down’s syndrome and AD-type dementia had shorter
T-cell telomeres than did age-matched controls [135].
Additionally, telomere length in leucocyte and buccal
cells were shorter in the younger and older AD patients
compared with the old control group. Surprisingly,
telomere length within the brain hippocampal tissue was
found to be 49% longer in the brain from AD patients
compared with normal control tissue. The underlying
mechanisms of these interesting phenomena remain to
be elucidated [134]. On the other hand, a couple of
studies were unable to conﬁrm the above association
[136,137]. Lukens et al. [136] found that leucocyte and
cerebellum telomere lengths were directly correlated in
AD patients. However, cerebellum telomere length was
not signiﬁcantly different between AD patients and age-
matched controls, possibly due to insufﬁcient power.
Zhang et al. [138] investigated the telomerase activity
of phytohaemagglutinin-activated lymphocytes from
AD patients. Telomerase activity in AD patients was
signiﬁcantly elevated compared with healthy controls
and vascular dementia patients, possibly as a response
to the telomere erosion accompanying the disease. In
addition, the telomerase activity of lymphocytes was
signiﬁcantlycorrelatedwiththedegreeofdementiainAD
patients, suggesting an accelerated telomere dysfunction
in lymphocytes and impaired immune function of AD
patients.
PD (Parkinson’s disease)
PD is another common neurodegenerative disorder in
the elderly characterized by a progressive degeneration
of dopaminergic neurons. Both inﬂammation and
oxidative stress contribute to the aetiology of PD.
Fewer studies have examined the relationship between
telomere length and PD. Wang et al. [139] showed
that men with shorter telomeres had a lower risk for
PD, which contrasts with the observations in other
aging-related diseases. In a study of 28 Japanese male
PD patients, leucocyte telomere length in PD patients
was not different from those in controls. However,
mean telomere length shorter than 5 kb was only found
in PD patients, suggesting that telomere shortening is
accelerated in PD patients [140]. Additionally, Maede
et al. [141] investigated the age-associated alterations of
subtelomeric methylation in Japanese PD patients. Short
telomeres with hypomethylated subtelomeres increased
with aging in the healthy controls, but did not change in
the PD patients.
Frailty
At the clinical level, the majority of the aging population
spends a variable period before death in a state of
declining function, described as the frailty syndrome,
representing an excess of deﬁcits over assets in a
dynamic state of balance, covering physical, functional,
psychological, nutritional and social domains [142,143].
The frailty index is a measure of frailty [144,145]. Few
data are available on telomere shortening and frailty,
although an association may be expected, since telomere
shortening is associated with many diseases and lifestyle
that predispose to frailty. In a large sample of Chinese
men and women aged 65 years and over, women were
frailer than men, but had longer telomere length. In men
only, there was a positive association between frailty
index and mortality. However, there was no correlation
between telomere length and frailty index in either sex
[143]. In the National Long Term Care Survey study,
leucocyte telomere length is predictive of disability of
older individuals in the U.S.A. population [146].
Longevity
Lifespan is determined by processes that are multi-
factorial and complex. Human longevity is at least
partly heritable, the genetic component being approx.
30% [147]. Mutations of Caenorhabditis elegans clk-2
gene, a homologue of yeast Tel2p, are associated with
longer telomere length and an extended lifespan [148].
In a cancer-resistant mouse model, mice constitutively
expressing the TERT had longer telomeres and extended
lifespan [149]. In humans, telomere length positively
correlates with years of healthy life [150]. Sequence
analysis of TERT and TERC showed overexpression of
synonymous and intronic mutations among Ashkenazi
centenarians relative to controls [151]. In addition,
variations in human telomerase gene are associated with
better maintenance of telomere length; longer telomeres
are associated with protection from age-related diseases,
better cognitive function, and lipid proﬁles, thus may
confer healthy aging and exceptional longevity [151].
Importantly, a common TERT haplotype associated with
longertelomerelengthisfoundinAshkenazicentenarians
and their offspring, indicating that TERT may function
as a genetic agent in lifespan determination [151].
Within-pair analyses of Swedish twins demonstrated
that telomere length at advanced age is a biomarker that
predicts survival beyond the impact of early familial
environment and genetic factors [152]. Similar results
were reported from the elderly Danish twin cohort.
The co-twin with the shorter telomeres died ﬁrst,
suggesting that telomere length is not only a biomarker
of aging, but also a determinant of lifespan [153]. By
contrast, some studies reported no apparent relationship
between telomere length and survival in elderly people or
centenarians [154,155].
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CONCLUSIONS AND FUTURE PERSPECTIVES
Most human studies in telomere biology and aging-
related diseases are cross-sectional in nature. Large-
scale and well-designed studies are lacking. Nonetheless,
emerging evidence demonstrates that telomere biology
is involved in the pathophysiology of aging and
human diseases. Whether telomere biology is causally
involved in the development of human diseases
awaits further research from large, prospective and
longitudinal as well as interventional studies. The answer
to this question may provide new prevention and
treatment opportunities to combat chronic aging-related
diseases. The telomere/telomerase system could be a
promising target, offering possibilities to increase the
viability of the cell for therapeutic purposes. Animal
studies demonstrated that several antihypertensive and
lipid-lowering drugs also increase telomerase activity
[156−158]. For example, ACEIs are safe, common and
long-used drugs whose use could be expanded beyond
the treatment of hypertension and into anti-aging [159].
Finally,moreresearchorclinicaltrialsareneededtoassess
the effects of lifestyle intervention and other medications
on the telomere/telomerase system. On the basis of the
promising in vitro and in vivo results, it is to be hoped
that telomerase-based prevention and therapeutics will
be utilized in the future to combat aging-related disease
including CVD.
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